Streamlining Oncology OptumRx Integration for Prior Authorization

Klivira streamlines oncology OptumRx integration, automating prior authorizations for high-cost biologics and oral oncolytics across complex cancer care pathways.

Oncology prior authorization is characterized by high-cost regimens, frequent changes, and a critical split between medical and pharmacy benefits. For practices managing patients with OptumRx coverage, navigating the specific requirements for both provider-administered and oral specialty drugs is paramount. Klivira's platform is engineered to address these complexities, ensuring efficient and compliant submissions.

The Challenge of Oncology Prior Authorization with OptumRx

Oncology care involves high-cost biologics, infusion therapy, radiation oncology, and frequent regimen adjustments. For patients covered by OptumRx, a leading PBM for UnitedHealthcare, managing prior authorizations for both medical and pharmacy benefits adds layers of complexity. This necessitates precise documentation and adherence to specific payer policies, particularly for oral oncolytics and supportive care medications processed through the PBM.

Key Prior Authorization Triggers in Oncology for OptumRx Patients

**J-code Chemotherapy and Biologic Infusions:** Each cycle and regimen change for IV agents typically triggers a PA event.
**Specialty Oral Oncolytics:** High-cost oral chemotherapy and targeted therapies (e.g., Gleevec, Tagrisso) require pharmacy benefit PA via OptumRx.
**Advanced Imaging:** PET/CT and advanced MRI for staging and surveillance often require medical benefit PA.
**Radiation Oncology Procedures:** IMRT, IGRT, SBRT, and proton-beam therapy CPT ranges necessitate treatment plan approvals.
**Supportive Care Medications:** Growth factors (G-CSF), ESAs, and antiemetics in extended regimens may require separate PBM PA.

Navigating Medical vs. Pharmacy Benefit for Oncology Drugs

A critical aspect of oncology PA is the split between medical and pharmacy benefits. Provider-administered IV chemotherapy and biologics fall under the medical benefit, typically requiring X12 278 or payer portal submissions. Oral oncology drugs, however, fall under the pharmacy benefit and are managed by PBMs like OptumRx, requiring ePA submissions via NCPDP SCRIPT or dedicated PBM portals. Klivira's platform intelligently routes these diverse requests to the correct channel.

Klivira's Approach to Oncology OptumRx Integration

Klivira’s platform is designed to streamline the specific demands of oncology prior authorization, including those for OptumRx patients. Our system integrates with your EMR to capture necessary clinical documentation, applying NCCN-compendium-aware policy logic to guide submissions. This ensures that documentation for diagnosis confirmation, prior-line treatment, performance status, and molecular markers is complete before submission, reducing common denial reasons like 'documentation gaps' or 'off-label use without compendium support'.

Optimizing Oncology PA Workflows with Klivira

**NCCN-Compendium-Aware Logic:** Surfaces required documentation per regimen and tumor type, aligning with payer medical necessity criteria.
**Regimen-Level PA Workflow:** Bundles related components (chemo + targeted + biologic) into a single submission where supported, or routes separately.
**Intelligent Benefit Routing:** Automatically directs medical benefit PAs to payer portals/X12 278 and pharmacy benefit PAs (e.g., to OptumRx) via ePA channels.
**Concurrent PA Tracking:** Manages the dozens of PA events per oncology patient, including supportive-care and surveillance imaging PAs.
**Peer-to-Peer Scheduling Integration:** Facilitates efficient scheduling for oncologist-payer reviews on clinical-necessity denials, minimizing treatment delays.

Addressing Common Oncology PA Denials with Klivira

Oncology PA denials frequently stem from off-label use without compendium support, step therapy requirements, or documentation gaps. Klivira's proactive approach helps mitigate these. By ensuring complete and accurate submissions aligned with NCCN guidelines and payer policies from the outset, we reduce the incidence of denials and accelerate approval times, especially crucial for the start-of-treatment urgency in cancer care.

Frequently asked questions

How does Klivira handle the medical vs. pharmacy benefit split for oncology drugs with OptumRx?

Klivira's platform intelligently identifies whether an oncology drug falls under the medical or pharmacy benefit. For oral oncolytics and other pharmacy benefit drugs covered by OptumRx, the system routes the PA request through ePA channels (e.g., NCPDP SCRIPT) directly to OptumRx. For IV infusions under the medical benefit, it routes via X12 278 or the appropriate payer portal.

What specific documentation does Klivira help gather for OptumRx oncology PAs?

Klivira leverages NCCN-compendium-aware logic to guide documentation requirements. This includes pathology reports, AJCC TNM staging, molecular markers (e.g., ER/PR/HER2, EGFR/ALK/PD-L1), prior-line treatment response, ECOG/Karnofsky performance status, and compendium citations for off-label use, all critical for OptumRx and other payer reviews.

Can Klivira manage the frequent regimen changes and multiple PAs per oncology patient?

Yes, Klivira is designed for the unique PA cadence of oncology. It supports regimen-level PA workflows, concurrent tracking of dozens of PA events per patient over a treatment course, and manages new PA cycles triggered by toxicity, progression, or response. This ensures continuous coverage as treatment plans evolve.

Does Klivira integrate with our EMR to streamline oncology OptumRx submissions?

Absolutely. Klivira integrates with leading EMRs via SMART on FHIR or other standard interfaces to extract relevant clinical data. This seamless integration populates PA forms automatically, reducing manual data entry and ensuring that the necessary clinical context is accurately transferred for OptumRx and other payer submissions.

How does Klivira address common denial reasons for oncology PAs from OptumRx?

Klivira's system proactively addresses common denial reasons by ensuring complete and accurate submissions from the outset. It highlights missing documentation, verifies NCCN Compendium support for off-label use, and helps identify potential step therapy conflicts. This reduces denials related to documentation gaps, lack of medical necessity, or policy non-compliance, streamlining the approval process.